[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605389":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":46,"studyPopulation":47,"armGroups":48,"interventions":54,"overallOfficials":59,"centralContacts":64,"locations":70,"responsibleParty":392,"collaborators":394,"id":398,"slug":399,"hasResults":400,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":400,"sex":406,"minAge":407,"maxAge":42,"enrollmentInfo":408,"targetDuration":411,"studyType":412,"phases":42,"briefSummary":413,"conditions":414,"keywords":419,"overallStatus":73,"whyStopped":42,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":434},{"fullName":5,"class":6},"Société Algérienne de Formation et de Recherche en Oncologie","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":24,"otherOutcomes":42},[9,13,17,20],{"measure":10,"description":11,"timeFrame":12},"Sociodemographic and clinical characteristics of lung cancer patients in Algeria","Patient age, sex, smoking history, comorbidities (e.g., COPD, diabetes, cardiovascular disease) and ECOG performance status, collected via eCRFs at inclusion in 21 oncology and pulmonology centers.","At baseline (inclusion)",{"measure":14,"description":15,"timeFrame":16},"Histological type and stage of lung cancer at diagnosis","Histological subtypes (NSCLC, SCLC, carcinoid tumors) and TNM stage of disease at diagnosis.","At baseline (diagnosis\u002Finclusion)",{"measure":18,"description":19,"timeFrame":12},"Molecular profile of tumors","Frequency of molecular alterations (EGFR, ALK, KRAS, PD-L1, ROS1, RET, HER2, NTRK1, BRAF, MET, PIK3CA, MEK1) identified in tumor samples at diagnosis.",{"measure":21,"description":22,"timeFrame":23},"First-line treatment modalities","Type of initial treatment received (surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy).","At baseline (initiation of treatment)",[25,29,32,35,38],{"measure":26,"description":27,"timeFrame":28},"Treatment-related toxicity according to CTCAE","Incidence, type, classification, severity, and impact of adverse events related to lung cancer treatments, assessed with CTCAE criteria.","From treatment initiation up to 12 months",{"measure":30,"description":31,"timeFrame":28},"Objective Response Rate (ORR)","Proportion of patients achieving complete or partial tumor response, assessed according to RECIST 1.1 criteria, based on real-world clinical and radiological data.",{"measure":33,"description":34,"timeFrame":28},"Progression-Free Survival (PFS)","Time from treatment initiation to first documented disease progression or death from any cause, whichever occurs first.",{"measure":36,"description":37,"timeFrame":28},"Time to Treatment Discontinuation (TTD)","Time from treatment initiation to discontinuation of therapy for any reason, including toxicity, disease progression, or patient\u002Fphysician decision.",{"measure":39,"description":40,"timeFrame":41},"Overall Survival (OS)","Time from date of diagnosis to death from any cause, based on real-world clinical follow-up.","Minimum 12-month follow-up after diagnosis",null,{"allocation":42,"interventionModel":42,"interventionModelDescription":42,"primaryPurpose":42,"observationalModel":44,"timePerspective":45,"maskingInfo":42},"COHORT","PROSPECTIVE","Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide, and its incidence continues to rise in Algeria. Despite this increasing burden, real-world data regarding the epidemiology, clinical management, and treatment outcomes of lung cancer remain limited at the national level. The SAFRO 2202 ALG-Lung Cancer Registry was established to fill this gap by systematically collecting prospective, real-life data from a large sample of patients managed within Algeria's public healthcare system.\n\nThis study is a prospective, multicenter, non-interventional observational registry conducted across 21 hospital centers specialized in oncology and pulmonology. It includes adult patients (aged ≥18 years) with a confirmed diagnosis of lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors. The study includes all patients diagnosed at the time of inclusion or within the 12 months preceding inclusion, provided they meet the eligibility criteria. All patients must be fully managed within the public healthcare system, including diagnosis, treatment, and follow-up.\n\nData will be collected as part of routine medical care, with no study-specific visits required, and will be entered into a secure electronic case report form (eCRF). Collected variables include demographic information, medical history, risk factors (especially smoking), tumor histology and molecular characteristics (e.g., EGFR, ALK, PD-L1, KRAS, ROS1, RET), ECOG performance status, and treatment modalities across different therapeutic lines.\n\nThe registry will also assess real-world treatment patterns and clinical outcomes, including objective response rate (based on RECIST 1.1), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS). Adverse events and treatment-related toxicities will be documented and classified according to international standards (CTCAE). A minimum of 1,500 patients per year is expected, with at least 12 months of follow-up per patient.\n\nThis project aims to create a reliable national database to support health policy, optimize therapeutic strategies, and guide clinical research. By accounting for variations in clinical practices and patient profiles across the country, SAFRO 2202 is expected to generate robust evidence to improve lung cancer care in Algeria.","Adult patients diagnosed with lung cancer (NSCLC, SCLC, or carcinoid tumors), recruited across 21 public or university hospitals in Algeria. Patients must have been diagnosed within 12 months prior to inclusion and be managed entirely within the public healthcare system.",[49],{"label":50,"type":42,"description":51,"interventionNames":52},"Lung Cancer Patients Cohort","Adult patients (≥18 years) diagnosed with lung cancer (NSCLC, SCLC, or carcinoid tumors) at the time of inclusion or within the previous 12 months, fully managed in oncology or pulmonology departments at one of the 21 participating public or university hospitals across Algeria. Data are collected prospectively during routine clinical care.",[53],"Other: Observational Data Collection",[55],{"type":6,"name":56,"description":57,"armGroupLabels":58,"otherNames":42},"Observational Data Collection","Collection of clinical, pathological, molecular, and treatment-related data during routine care, with no additional procedures or interventions required by the study.",[50],[60],{"name":61,"affiliation":62,"role":63},"Adda BOUNEDJAR, Professor of Medical Oncology","Frantz Fanon University Hospital, Cancer Center (CAC), Blida, Algeria","PRINCIPAL_INVESTIGATOR",[65],{"name":66,"role":67,"phone":68,"phoneExt":42,"email":69},"Louisa ISSIAKHEM LOUNICI, CEO","CONTACT","+213 770 48 43 36","l.issiakhem@cmsolutionsdz.com",[71,92,104,116,128,140,156,172,187,204,221,233,250,267,284,296,308,325,341,358,375],{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"Centre Pierre et Marie Curie","RECRUITING","Algiers","Algiers Province","16000","Algeria","DZ",{"type":80,"coordinates":81},"Point",[82,83],3.08746,36.73225,{"lat":83,"lon":82},[86,90],{"name":87,"role":67,"phone":88,"phoneExt":42,"email":89},"Esma KERBOUA, MD","+213 770 86 81 10","esmakerboua@yahoo.fr",{"name":91,"role":63,"phone":42,"phoneExt":42,"email":42},"Esma KERBOUA, Professor of Medical Oncology",{"facility":93,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":94,"geoPoint":96,"contacts":97},"Chu Beni Messous - Isaad Hassani",{"type":80,"coordinates":95},[82,83],{"lat":83,"lon":82},[98,102],{"name":99,"role":67,"phone":100,"phoneExt":42,"email":101},"Merzak GHARNAOUT, MD","+213 561 27 06 89","mergharnaout@yahoo.fr",{"name":103,"role":63,"phone":42,"phoneExt":42,"email":42},"Merzak GHARNAOUT, Professor of Pulmonology",{"facility":105,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":106,"geoPoint":108,"contacts":109},"CHU Mohamed Lamine Debaghine - Bab-el-Oued",{"type":80,"coordinates":107},[82,83],{"lat":83,"lon":82},[110,114],{"name":111,"role":67,"phone":112,"phoneExt":42,"email":113},"Souad SOUILAH, MD","+213 550 39 62 70","souad.souilah@gmail.com",{"name":115,"role":63,"phone":42,"phoneExt":42,"email":42},"Souad SOUILAH, Professor of Pulmonology",{"facility":117,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":118,"geoPoint":120,"contacts":121},"Chu-Beni Messous - Isaad Hassani",{"type":80,"coordinates":119},[82,83],{"lat":83,"lon":82},[122,126],{"name":123,"role":67,"phone":124,"phoneExt":42,"email":125},"Mohammed OUKKAL, MD","+213 771 446 908","mohammedoukkal@gmail.com",{"name":127,"role":63,"phone":42,"phoneExt":42,"email":42},"Mohammed OUKKAL, Professor of Medical Oncology",{"facility":129,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":130,"geoPoint":132,"contacts":133},"EPH Rouiba",{"type":80,"coordinates":131},[82,83],{"lat":83,"lon":82},[134,138],{"name":135,"role":67,"phone":136,"phoneExt":42,"email":137},"Hassen MAHFOUF, MD","+213 550 59 40 60","mahfoufhassen@gmail.com",{"name":139,"role":63,"phone":42,"phoneExt":42,"email":42},"Hassen MAHFOUF, Professor of Medical Oncology",{"facility":141,"status":73,"city":142,"state":142,"zip":143,"country":77,"countryCode":78,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"CLCC Annaba","Annaba","23000",{"type":80,"coordinates":145},[146,147],7.76667,36.9,{"lat":147,"lon":146},[150,154],{"name":151,"role":67,"phone":152,"phoneExt":42,"email":153},"Hanène DJEDI, MD","+213 550 52 40 38","djedi_hanene@yahoo.fr",{"name":155,"role":63,"phone":42,"phoneExt":42,"email":42},"Hanène DJEDI, Professor of Medical Oncology",{"facility":157,"status":73,"city":158,"state":159,"zip":42,"country":77,"countryCode":78,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"CLCC Batna","Batna City","Batna",{"type":80,"coordinates":161},[162,163],6.17414,35.55597,{"lat":163,"lon":162},[166,170],{"name":167,"role":67,"phone":168,"phoneExt":42,"email":169},"Wassila BENBRAHIM, MD","+213 663 373 369","w.khemilet@gmail.com",{"name":171,"role":63,"phone":42,"phoneExt":42,"email":42},"Wassila BENBRAHIM, Professor of Medical Oncology",{"facility":173,"status":73,"city":174,"state":175,"zip":42,"country":77,"countryCode":78,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"CAC-CHU Frantz Fanon","Blida","Blida Province",{"type":80,"coordinates":177},[178,179],2.8277,36.47004,{"lat":179,"lon":178},[182,186],{"name":183,"role":67,"phone":184,"phoneExt":42,"email":185},"Adda BOUNEDJAR, MD","+213 661 651 010","a_bounedjar@yahoo.fr",{"name":61,"role":63,"phone":42,"phoneExt":42,"email":42},{"facility":188,"status":73,"city":189,"state":190,"zip":191,"country":77,"countryCode":78,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"CHU- Hôpital Khelil Amrane","Béjaïa","Béjaia Province","06000",{"type":80,"coordinates":193},[194,195],5.08433,36.75587,{"lat":195,"lon":194},[198,202],{"name":199,"role":67,"phone":200,"phoneExt":42,"email":201},"Chahira MAZOUZI, MD","+213 553 68 20 71","shala_gouri@hotmail.com",{"name":203,"role":63,"phone":42,"phoneExt":42,"email":42},"Chahira MAZOUZI, Professor of Medical Oncology",{"facility":205,"status":73,"city":206,"state":207,"zip":208,"country":77,"countryCode":78,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"CHU Dr Abdesselam Benbadis","Constantine","Constantine Province","25000",{"type":80,"coordinates":210},[211,212],6.61472,36.365,{"lat":212,"lon":211},[215,219],{"name":216,"role":67,"phone":217,"phoneExt":42,"email":218},"Taha FILALI, MD","+213 671 69 60 75","tahafilali@gmail.com",{"name":220,"role":63,"phone":42,"phoneExt":42,"email":42},"Taha FILALI, Professor of Medical Oncology",{"facility":222,"status":73,"city":206,"state":207,"zip":208,"country":77,"countryCode":78,"cosmosGeoPoint":223,"geoPoint":225,"contacts":226},"EH Didouche Mourad",{"type":80,"coordinates":224},[211,212],{"lat":212,"lon":211},[227,231],{"name":228,"role":67,"phone":229,"phoneExt":42,"email":230},"Assia BENSALEM, MD","+213 661 51 44 88","assiabensalem@yahoo.fr",{"name":232,"role":63,"phone":42,"phoneExt":42,"email":42},"Assia BENSALEM, Professor of Medical Oncology",{"facility":234,"status":73,"city":235,"state":236,"zip":237,"country":77,"countryCode":78,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"CLCC Draâ Ben Khedda","Tizi Ouzou","Draâ Ben Khedda","15100",{"type":80,"coordinates":239},[240,241],4.04591,36.71182,{"lat":241,"lon":240},[244,248],{"name":245,"role":67,"phone":246,"phoneExt":42,"email":247},"Cherifa SEDKAOUI, MD","+213 552 05 00 65","csedkaoui@yahoo.fr",{"name":249,"role":63,"phone":42,"phoneExt":42,"email":42},"Cherifa SEDKAOUI, Professor of Medical Oncology",{"facility":251,"status":73,"city":252,"state":253,"zip":254,"country":77,"countryCode":78,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"CAC-Laghouat","Laghouat","Laghouat Province","03000",{"type":80,"coordinates":256},[257,258],2.86514,33.8,{"lat":258,"lon":257},[261,265],{"name":262,"role":67,"phone":263,"phoneExt":42,"email":264},"Zakia Batoul BENLAHRECH, MD","+213 657 325 700","z.benlahrech@lagh-univ.dz",{"name":266,"role":63,"phone":42,"phoneExt":42,"email":42},"Zakia Batoul BENLAHRECH, Professor of Medical Oncology",{"facility":268,"status":73,"city":269,"state":270,"zip":271,"country":77,"countryCode":78,"cosmosGeoPoint":272,"geoPoint":276,"contacts":277},"CAC Oran EL HASSI- EMIR ABDELKADER","Oran","Oran Province","31000",{"type":80,"coordinates":273},[274,275],-0.63588,35.69906,{"lat":275,"lon":274},[278,282],{"name":279,"role":67,"phone":280,"phoneExt":42,"email":281},"Blaha LARBAOUI, MD","+213 560 33 02 01","larbaoui_onco@yahoo.fr",{"name":283,"role":63,"phone":42,"phoneExt":42,"email":42},"Blaha LARBAOUI, Professor of Medical Oncology",{"facility":285,"status":73,"city":269,"state":270,"zip":271,"country":77,"countryCode":78,"cosmosGeoPoint":286,"geoPoint":288,"contacts":289},"CHU Dr. Benaouda Benzerdjeb",{"type":80,"coordinates":287},[274,275],{"lat":275,"lon":274},[290,294],{"name":291,"role":67,"phone":292,"phoneExt":42,"email":293},"Abdelkader BOUSAHBA, MD","+213 559 85 56 93","aekbousahba@yahoo.fr",{"name":295,"role":63,"phone":42,"phoneExt":42,"email":42},"Abdelkader BOUSAHBA, Professor of Medical Oncology",{"facility":297,"status":73,"city":269,"state":270,"zip":271,"country":77,"countryCode":78,"cosmosGeoPoint":298,"geoPoint":300,"contacts":301},"EHS 1er novembre",{"type":80,"coordinates":299},[274,275],{"lat":275,"lon":274},[302,306],{"name":303,"role":67,"phone":304,"phoneExt":42,"email":305},"Faiza BEREKSI REGUIG, MD","+213 662 69 80 78","faizabereksireguig@yahoo.fr",{"name":307,"role":63,"phone":42,"phoneExt":42,"email":42},"Faiza BEREKSI REGUIG, Professor of Medical Oncology",{"facility":309,"status":73,"city":310,"state":311,"zip":312,"country":77,"countryCode":78,"cosmosGeoPoint":313,"geoPoint":317,"contacts":318},"CAC- Ouargla","Ouargla","Ouargla Province","30000",{"type":80,"coordinates":314},[315,316],5.32502,31.94932,{"lat":316,"lon":315},[319,323],{"name":320,"role":67,"phone":321,"phoneExt":42,"email":322},"Hanina FIZI, MD","+213 775 18 23 50","haninaf@yahoo.fr",{"name":324,"role":63,"phone":42,"phoneExt":42,"email":42},"Hanina FIZI, Medical Oncologist",{"facility":326,"status":73,"city":327,"state":328,"zip":329,"country":77,"countryCode":78,"cosmosGeoPoint":330,"geoPoint":334,"contacts":335},"CAC El OUED","El Oued","Oued Souf","39000",{"type":80,"coordinates":331},[332,333],6.86319,33.35608,{"lat":333,"lon":332},[336,339],{"name":337,"role":67,"phone":124,"phoneExt":42,"email":338},"Ahmed Zaki SADANI, MD","time2@hotmail.fr",{"name":340,"role":63,"phone":42,"phoneExt":42,"email":42},"Ahmed Zaki SADANI, Professor of Medical Oncology",{"facility":342,"status":73,"city":343,"state":344,"zip":345,"country":77,"countryCode":78,"cosmosGeoPoint":346,"geoPoint":350,"contacts":351},"CAC- Sidi Bel Abbès","Sidi Bel Abbes","Sidi Bel Abbès Province","22000",{"type":80,"coordinates":347},[348,349],-0.63085,35.18994,{"lat":349,"lon":348},[352,356],{"name":353,"role":67,"phone":354,"phoneExt":42,"email":355},"Djamila YEKROU, MD","+213 549 79 11 28","djyekrou@yahoo.fr",{"name":357,"role":63,"phone":42,"phoneExt":42,"email":42},"Djamila YEKROU, Professor of Medical Oncology",{"facility":359,"status":73,"city":360,"state":361,"zip":362,"country":77,"countryCode":78,"cosmosGeoPoint":363,"geoPoint":367,"contacts":368},"EPH- Sidi Ghiles","Tipasa","Sidi Ghiles","42115",{"type":80,"coordinates":364},[365,366],2.44889,36.58972,{"lat":366,"lon":365},[369,373],{"name":370,"role":67,"phone":371,"phoneExt":42,"email":372},"Fatma SEGHIER, MD","+213 540 464 853","seghierfatma@yahoo.fr",{"name":374,"role":63,"phone":42,"phoneExt":42,"email":42},"Fatma SEGHIER, Professor of Medical Oncology",{"facility":376,"status":73,"city":377,"state":378,"zip":379,"country":77,"countryCode":78,"cosmosGeoPoint":380,"geoPoint":384,"contacts":385},"CAC-Sétif","Sétif","Sétif Province","19000",{"type":80,"coordinates":381},[382,383],5.41373,36.19112,{"lat":383,"lon":382},[386,390],{"name":387,"role":67,"phone":388,"phoneExt":42,"email":389},"Hussein Adlane DIB, MD","+213 770 915 912","oncosetif@gmail.com",{"name":391,"role":63,"phone":42,"phoneExt":42,"email":42},"Hussein Adlane DIB, Professor of Medical Oncology",{"type":393,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR",[395],{"name":396,"class":397},"AstraZeneca","INDUSTRY","100605389","alg-lungcancerregistry-safro2202-100605389",false,"NCT07161882","ALG-LungCancerRegistry (SAFRO2202)","Observational Study of the Epidemiological, Clinical, and Diagnostic Profile, Treatment Patterns, and Outcomes of Lung Cancer.","SAFRO2202","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor)\n* Diagnosed at the time of inclusion or within the 12 previous months\n* Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public\u002Funiversity hospitals\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Prior enrollment in this study\n* Participation in an interventional clinical trial","ALL","18 Years",{"count":409,"type":410},3750,"ESTIMATED","12 Months","OBSERVATIONAL","SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors.\n\nEligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required.\n\nThe study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS).\n\nThe findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.",[415,416,417,418],"Lung Neoplasms","Carcinoma, Non-Small-Cell Lung","Carcinoma, Small Cell","Carcinoid Tumor",[420,421,418,422,423,424,77],"Lung Cancer","Non-Small Cell Lung Cancer","Treatment Outcomes","Drug-Related Side Effects","Registries","2025-09-12",{"date":427,"type":428},"2025-09-16","ACTUAL",{"date":430,"type":428},"2025-06-01",{"date":432,"type":410},"2027-12",{"name":5,"class":6},21]